Molecular Tumor Board: 77-year-old female with metastatic breast cancer with PIK3CA H1047R mutation and 83-year-old female with metastatic breast cancer with AKT1 L52R mutation

Dr. Marcela Mazo Canola, Assistant Professor of Medicine, Breast Medical Oncology at UT Health San Antonio Mays Cancer Center joined our Oncology Medical Affairs Directors, Kyle Strickland and Heidi Ko to discuss the importance of biomarker testing for therapeutic implications in metastatic breast cancer. Two cases of metastatic hormone receptor-positive, HER2-negative breast cancer with PIK3CA and AKT1 alterations were discussed.

Labcorp Perspectives - Oncology: Understanding an inflamed tumor microenvironment and how to leverage it for targeted therapy(Episode 1)

Analytical Validation of the Labcorp® Plasma Complete™ Test to Enable Precision Oncology Through Solid Tumor Liquid Biopsy Comprehensive Genomic Profiling

A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability

Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer suggests a mechanism of immune evasion and tumor progression

Novel HLA-Ilo/HLA-IIhi phenotype suggests pattern of immune evasion in triple-negative breast cancer

Equitable Inclusion of Diverse Populations in Oncology Clinical Trials: Deterrents and Drivers

Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer

OX40/OX40 Ligand and its Role in Precision Immune Oncology

White Paper: Molecular Alterations in Non-Small Cell Lung Cancer